Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Triguero, Ana
• dc.contributor.author Vélez, Patricia
• dc.contributor.author Bellosillo Paricio, Beatriz
• dc.contributor.author MPN Spanish Group (GEMFIN)
• dc.date.accessioned 2024-01-08T06:45:51Z
• dc.date.available 2024-01-08T06:45:51Z
• dc.date.issued 2022
• dc.description.abstract Hematological control, incidence of complications, and need for cytoreduction were studied in 453 patients with low-risk polycythemia vera (PV) treated with phlebotomies alone. Median hematocrit value decreased from 54% at diagnosis to 45% at 12 months, and adequate hematocrit control over time (< 45%) was observed in 36%, 44%, and 32% of the patients at 6, 12, and 24 months, respectively. More than 5 phlebotomies per year in the maintenance phase were required in 19% of patients. Worsening thrombocytosis, age > 60 years, and microvascular symptoms constituted the main indications for starting cytoreduction. Median duration without initiating cytoreduction was significantly longer in patients younger than 50 years (< 0.0001). The incidence rate of thrombosis under phlebotomies alone was 0.8% per year and the estimated probability of thrombosis at 10 years was 8.5%. The probability of arterial thrombosis was significantly higher in patients with arterial hypertension whereas there was a trend to higher risk of venous thrombosis in cases with high JAK2V617F allele burden. Rates of major bleeding and second primary neoplasm were low. With a median follow-up of 9 years, survival probability at 10 years was 97%, whereas the probability of myelofibrosis at 10 and 20 years was 7% and 20%, respectively. Progression to acute myeloid leukemia was documented in 3 cases (1%). Current management of low-risk PV patients is associated with low rate of thrombosis and long survival. New treatment strategies are needed for improving hematological control and, in the long term, reducing progression to myelofibrosis.
• dc.format.mimetype application/pdf
• dc.identifier.citation Triguero A, Pedraza A, Pérez‑Encinas M, Mata‑Vázquez MI, Vélez P, Fox L, et al. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. Ann Hematol. 2022;101(10):2231-9. DOI: 10.1007/s00277-022-04963-z
• dc.identifier.doi http://dx.doi.org/10.1007/s00277-022-04963-z
• dc.identifier.issn 0939-5555
• dc.identifier.uri http://hdl.handle.net/10230/58617
• dc.language.iso eng
• dc.publisher Springer
• dc.relation.ispartof Ann Hematol. 2022;101(10):2231-9
• dc.rights © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Low-risk
• dc.subject.keyword Myelofibrosis
• dc.subject.keyword Phlebotomies
• dc.subject.keyword Polycythemia vera
• dc.subject.keyword Thrombosis
• dc.title Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion